Keywords: داکلیزومب; AE; adverse event; ALT; alanine aminotransferase; AST; aspartate aminotransferase; DRESS; drug reaction with eosinophilia and systematic symptoms; DSMB; data safety monitoring board; GGT; gamma-glutamyl transferase; GI; gastrointestinal; IL-2; interleukin
مقالات ISI داکلیزومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab
Keywords: داکلیزومب; Multiple sclerosis; Natalizumab; Daclizumab; Alemtuzumab;
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Keywords: داکلیزومب; Antitumor immunity; Daclizumab; Regulatory T cells;
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
Keywords: داکلیزومب; ARR; annualized relapse rate; BDI-II; Beck Depression Inventory-II; EQ-5D; Euro-Qol 5-Dimensions; IFN; interferon; IM; intramuscular; MRI; magnetic resonance imaging; MS; multiple sclerosis; MSIS-29; 29-item Multiple Sclerosis Impact Scale; OR; odds ratio
Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8 years of follow-up
Keywords: داکلیزومب; Renal transplantation; Rabbit antithymocyte globulin; Daclizumab; Alemtuzumab; Tacrolimus; Enteric-coated mycophenolate sodium; Steroid avoidance; Biopsy-proven acute rejection; Graft survival;
Short communicationCirculating innate lymphoid cells are unchanged in response to DAC HYP therapy
Keywords: داکلیزومب; Daclizumab; Innate lymphoid cell; ILC; Natural killer; NK;
Daclizumab (anti-CD25) in multiple sclerosis
Keywords: داکلیزومب; CEL; Contrast enhancing lesion; CSF; Cerebrospinal fluid; DAC; Daclizumab; EDSS; Expanded Disability Status Scale; MSFC; Multiple Sclerosis Functional Composite; MSIS; Multiple Sclerosis Impact Scale; NRS; Neurological Rating Scale; RRMS; Relapsing-remitt
Nuevos tratamientos para la esclerosis múltiple
Keywords: داکلیزومب; Esclerosis múltiple; Alemtuzumab; Cladribina; Daclizumab; Dalfampridina; Dimetil fumarato; Fingolimod; Laquinimod; Rituximab; TeriflunomidaMultiple sclerosis; Alemtuzumab; Cladribine; Daclizumab; Dalfampridine; Dimethyl fumarate; Fingolimod; Laquinimod; R
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
Keywords: داکلیزومب; Multiple sclerosis; Immunomodulatory therapy; Monoclonal antibody treatment; Daclizumab; Anti-CD25
FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy
Keywords: داکلیزومب; Tregs, regulatory T cells; PBMC, peripheral blood mononuclear cells; OPD, o-phenylenediamine dihydrochloride; BSA, bovine serum albuminTregs; Regulatory T cells; Daclizumab; Anti-CD25; Islet transplantation; FoxP3
Anticuerpos monoclonales en desarrollo en esclerosis múltiple
Keywords: داکلیزومب; Anticuerpo monoclonal; Esclerosis múltiple; Alemtuzumab; Daclizumab; Rituximab; OcrelizumabMonoclonal antibody; Multiple sclerosis; Alemtuzumab; Daclizumab; Rituximab; Ocrelizumab
Promising Emerging Therapies for Multiple Sclerosis
Keywords: داکلیزومب; Alemtuzumab; Daclizumab; BG-12; Fumarate; Cladribine; Fingolimod; Laquinimod; Teriflunomide;
Traitements actuels de la SEP
Keywords: داکلیزومب; sclérose en plaques; immunosuppresseurs; immunomodulateurs; interférons β-1; méthylprednisolone; anticorps monoclonaux; fingolimod; laquinimod; tériflunomide; alemtuzumab; daclizumab; rituximab
Safety of minimal immunosuppression in liver transplantation for hepatoblastoma
Keywords: داکلیزومب; Hepatoblastoma; Liver transplantation; Minimal immunosuppression; Daclizumab; Tacrolimus; Rejection-free survival;
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis
Keywords: داکلیزومب; Daclizumab; Posterior uveitis; Panuveitis; Intermediate uveitis; Interleukin-2
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period
Keywords: داکلیزومب; Alemtuzumab; Daclizumab; Immunosuppression; Induction therapy;
Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation
Keywords: داکلیزومب; Heart transplantation; T regulatory cells; Rejection; FOXP3; Daclizumab
A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex
Keywords: داکلیزومب; Monoclonal antibody; Immune regulation; Cytokines; Interleukin-2; Daclizumab; CD25;
Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?
Keywords: داکلیزومب; Daclizumab; Interleukin-2; CD25; Signal transduction; Transplantation;
Design of humanized antibodies: From anti-Tac to Zenapax
Keywords: داکلیزومب; Antibody engineering; Antigen-binding affinity; Daclizumab; Effector functions; Immunogenicity; Molecular biology; Molecular modeling; Protein expression; Sequence homology;